Drug Trial Radar · NCT05642312
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Jan 9, 2023
Primary completion
Dec 9, 2024
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Conditions
- Uveitic Macular Edema
Interventions
VamikibartDrug
Participants will receive vamikibart IVT injection
ShamOther
Participants will receive a sham procedure that mimics an IVT injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with ≥ 15 letter improvement from baseline in best-corrected visual acuity (BCVA) at Week 16Time frame: Week 16
Locations
77 sites in 14 countries. Site status is shown where the registry gives one.
Kaiser Permanente Southern California
Los Angeles, California
Colorado Retina Associates, PC
Lakewood, Colorado
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Cumberland Valley Retina PC
Hagerstown, Maryland
VitreoRetinal Surgery, PLLC.
Minneapolis, Minnesota
Truhlsen Eye Institute
Omaha, Nebraska
Envision Ocular, LLC
Bloomfield, New Jersey
Wake Forest Baptist Health Eye Centre
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University Investigational Drug Services
Columbus, Ohio
Oregon Health & Science Uni
Portland, Oregon
Erie Retina Research
Erie, Pennsylvania
Palmetto Retina Center
West Columbia, South Carolina
Tennessee Retina PC
Nashville, Tennessee
Austin Clinical Research LLC
Austin, Texas
Texas Retina Associates
Dallas, Texas
LKH-Univ.Klinikum Graz
Graz, Austria
Kepler Universitätskliniken GmbH - Med Campus III
Linz, Austria
Medizinische Universitat Wien
Vienna, Austria
Fiocruz - Fundação Oswaldo Cruz
Rio de Janeiro, Brazil
Retina Clinic
São Paulo, São Paulo, Brazil
Universidade Federal de Sao Paulo - UNIFESPX
São Paulo, São Paulo, Brazil
CEMAPE - Centro Médico
São Paulo, São Paulo, Brazil
CHU de Quebec-Universite Laval
Québec, Canada
Kensington Vision and Research Centre
Toronto, Ontario, Canada
Hôpital Maisonneuve - Rosemont
Montreal, Quebec, Canada
Peking Union Medical College Hospital
Beijing, China
Beijing Tongren Hospital
Beijing, China
The Second Hospital of Jilin University
Changchun, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, China
Second Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, China
Shanghai First People's Hospital
Shanghai, China
Tianjin Medical University Eye Hospital
Tianjin, China
Eye Hospital, Wenzhou Medical University
Wenzhou, China
Ren Min Hospital Affiliated Wu Han University
Wuhan, China
Rambam Medical Center
Haifa, Israel
Hadassah MC
Jerusalem, Israel
Meir Medical Center
Kfar Saba, Israel
Rabin MC
Petah Tikva, Israel
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.